Ferrocene-Conjugated L-Tryptophan Copper(II) Complexes of Phenanthroline Bases Showing DNA Photocleavage Activity and Cytotoxicity

ArticleinInorganic Chemistry 50(17):8452-64 · July 2011with51 Reads
DOI: 10.1021/ic201028e · Source: PubMed
Ferrocene-conjugated L-tryptophan (L-Trp) reduced Schiff base (Fc-TrpH) copper(II) complexes [Cu(Fc-Trp)(L)](ClO(4)) of phenanthroline bases (L), viz. 2,2'-bipyridine (bpy in 1), 1,10-phenanthroline (phen in 2), dipyrido[3,2-d:2',3'-f]quinoxaline (dpq in 3), and dipyrido[3,2-a:2',3'-c]phenazine (dppz in 4), were prepared and characterized and their photocytotoxicity studied. Cationic reduced Schiff base (Ph-TrpH) complexes [Cu(Ph-Trp)(L)(H(2)O)](ClO(4)) (L = phen in 5; dppz in 6) having the ferrocenyl moiety replaced by a phenyl group and the Zn(II) analogue (7) of complex 4 were prepared and used as control species. The crystal structures of 1 and 5 with respective square-planar CuN(3)O and square-pyramidal CuN(3)O(2) coordination geometry show significantly different core structures. Complexes 1-4 exhibit a Cu(II)-Cu(I) redox couple near -0.1 V and the Fc(+)-Fc couple at ~0.5 V vs SCE in DMF-0.1 M [Bu(n)(4)N](ClO(4)) (Fc = ferrocenyl moiety). The complexes display a copper(II)-based d-d band near 600 nm and a Fc-centered band at ~450 nm in DMF-Tris-HCl buffer. The complexes are efficient binders to calf thymus DNA. They are synthetic chemical nucleases in the presence of thiol or H(2)O(2), forming hydroxyl radicals. The photoactive complexes are cleavers of pUC19 DNA in visible light, forming hydroxyl radicals. Complexes 2-6 show photocytotoxicity in HeLa cancer cells, giving IC(50) values of 4.7, 10.2, 1.3, 4.8, and 4.3 μM, respectively, in visible light with the appearance of apoptotic bodies. The complexes also show photocytotoxicity in MCF-7 cancer cells. Nuclear chromatin cleavage has been observed with acridine orange/ethidium bromide (AO/EB) dual staining with complex 4 in visible light. The complexes induce caspase-independent apoptosis in the HeLa cells.
    • "By changing the substituents at the Cu(N-N) moiety with the inclusion of extended planar heterocyclic bases and maintaining acac as co-ligand [132], or by replacing gly with other aminoacids such as L-val [133] [134], L-phe [135] [136], L-tyr [137] and L-trp [138] in combination with several diimines , other research groups on the whole confirmed that these complexes bound to and (photo)cleaved DNA via ROS generation. "
    [Show abstract] [Hide abstract] ABSTRACT: Conventional chemotherapy and radiation treatment are two cornerstones of the cancer treatments, but efforts are required to improve their "therapeutic window". The development of metal complexes including platinum has had an enormous impact on current cancer chemotherapy. However, these chemotherapic drugs can be employed only in the management of a limited number of cancers and, furthermore, their use shows important side effects. Research in the past 10 years has produced new complexes containing heavy atoms other than platinum, like iron, cobalt, or gold, which have been used in phase I and phase II trials. Recent preclinical research has shown promising results also using titanium, ruthenium, copper and silver. The anticancer activity of metal based compounds and nanoparticles (gold and gadolinium in particular) is presently under evaluation in several laboratories in combination or not with X-ray therapy. In fact, if present in sufficiently high concentrations into the tumors, metals can act as a radiotherapy adjuvant: they possess an increased capability to absorb the X-ray radiation with respect to the water-based tissues. Low energy electrons will be then released close to the metal, and therefore determine a local dose enhancement. This review will focus on the anticancer properties of new drugs and on the rationale for testing their usefulness in combined treatment.
    Full-text · Article · Feb 2014
    • "In addition , methionine's major role in preventing cancer development is based on the fact that it is the primary methyl donor in cells. The complexes of amino acids act as good chelating agents [9], efficient biologically active [10] and cytotoxic agents [11]. Although few of these metal complexes have also entered phase I and phase II clinical trials [12], their precise mechanism of action and health hazards viz. "
    [Show abstract] [Hide abstract] ABSTRACT: This work reports an effort to understand the role of amino acid with DNA interactions in binding of biologically imperative metallointercalators [Cu(II), Ni(II) and Zn(II)], incorporated by benzylidine-4-aminoantipyrine (L) and l-methionine (Met) ligands. Herein, the pre-clinical evaluations of synthesized amino acid mixed-ligand complexes, inflammatory response and analgesic activity, have been done. In vivo and in vitro anti-tumor functions of the complexes against Ehrlich ascites carcinoma tumor model have been investigated. All these metal chelates are strong SOD mimetic compounds and also behave as peroxyl radical scavengers. Towards non-cancerous cell line, Cu(II) complex exhibits very low toxicity. On the other hand all the complexes have been found to exhibit cytotoxic effects against cancerous cell lines with potency more than that of the widely used drug cisplatin and hence they have the potential to act as promising anticancer agents. Captivatingly, they are non-toxic to normal cell lymphocytes, revealing that they are selective in killing only the cancer cells.
    Full-text · Article · Jan 2014
  • [Show abstract] [Hide abstract] ABSTRACT: Ferrocene-conjugated reduced Schiff base (Fc-metH) copper(II) complexes of L-methionine and phenanthroline bases, namely, [Cu(Fc-met)(B)](NO3), where B is 1,10-phenanthroline (phen in 1), dipyrido[3,2-d:2',3'-f]quinoxaline (dpq in 2), dipyrido[3,2-a:2',3'-c]phenazine (dppz in 3), and 2-(naphthalen-1-yl)-1H-imidazo[4,5-f][1,10]phenanthroline (nip in 4), were prepared and characterized and their photocytotoxicity studied (Fc = ferrocenyl moiety). Complexes [Cu(Ph-met)(B)](NO3) of the reduced Schiff base from benzaldehyde and L-methionine (Ph-metH) and B (phen in 5, dppz in 6) were prepared and used as control species. Complexes 1 and 5 were structurally characterized by X-ray crystallography. Complex 1 as a discrete monomer has a CuN3OS core with the thiomethyl group as the axial ligand. Complex 5 has a polymeric structure with a CuN3O2 core in the solid state. Complexes 5 and 6 are formulated as [Cu(Ph-met)(B)(H2O)] (NO3) in an aqueous phase based on the mass spectral data. Complexes 1-4 showed the Cu(II)-Cu(I) and Fc(+)-Fc redox couples at similar to 0.0 and similar to 0.5 V vs SCE, respectively, in DMF-0.1 M [(Bu4N)-N-n](ClO4). A Cu(II)-based weak d-d band near 600 nm and a relatively strong ferrocenyl band at similar to 450 nm were observed in DMF-Tris-HCl buffer (1:4 v/v). The complexes bind to calf thymus DNA, exhibit moderate chemical nuclease activity forming (OH)-O-center dot radical species, and are efficient photocleavers of pUC19 DNA in visible light of 454, 568, and 647 rim, forming (OH)-O-center dot radical as the reactive oxygen species. They are cytotoxic in HeLa (human cervical cancer) and MCF-7 (human breast cancer) cells, showing an enhancement of cytotoxicity upon visible light irradiation. Significant change in the nuclear morphology of the HeLa cells was observed with 3 in visible light compared to the nonirradiated sample. Confocal imaging using 4 showed its nuclear localization within the HeLa cells.
    Full-text · Article · Nov 2011
Show more